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Abbreviations 
acute lymphoblastic leukaemia (ALL) 
B-cell lymphoma 2 ( Bcl-2) 
B-cell lymphoma/leukemia 11B protein (Bcl-B) 
B-cell lymphoma-extra large (Bcl-xL) 
Bcl-2-associated death promoter (Bad) 
Bcl-2-associated protein (Bax) 
Bcl-2-homologous antagonist killer (Bak) 
Bcl-2-like protein 2 (Bcl-w) 
BH3 interacting-domain death agonist (Bid) 
Chronic lymphocytic leukemia (CLL) 
induced myeloid leukemia cell differentiation protein (Mcl-1) 
mammalian target of rapamycin protein (mTOR) 
mouse double minute 2 (MDM2) 
NF-kappa-B-inducing kinase (NIK) 
Nuclear Factor-kappa-B (NF-κB) 
p53 upregulated modulator of apoptosis (PUMA) 
Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) 
small cell lung cancer (SCLC) 
second mitochondria-derived activator of caspases (Smac) 
small lymphocytic leukemia (SLL) 
truncated BH3 interacting-domain death agonist (t-Bid) 
TNF-related apoptosis-inducing ligand (TRAIL) 
X-linked inhibitor of apoptosis protein (XIAP)  
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Abstract 
The study of cellular mechanisms of cancer growth and survival has revealed a complex web of signalling pathways that produce 
the ‘hallmarks of cancer’. A number of critical cellular signalling nodes have been characterised from which many new drug 
targets have been proposed. A number of these nodes are regulated by protein-protein interactions, and so present attractive, if 
challenging, targets for drug discovery. Drug discovery efforts towards three PPI families have resulted in clinically investigated 
drugs: i.e. Bcl-2 family inhibitors, MDM2-p53 inhibitors and IAP inhibitors. The discovery and optimisation of these drug classes 
are detailed in this chapter. 
PPI targets in cancer 
The modern understanding of cancer biology is that tumour cells have acquired the characteristic ‘hallmarks of cancer’ through 
gain-of-function mutations to oncogenes and loss-of-function of tumour suppressor genes.1 Detailed examination of signalling 
pathways associated with hallmark traits has allowed the identification of numerous potential targets for intervention by 
therapeutic agents, in many cases with small-molecule drugs. A number of the pathways investigated thus far rely on signalling 
via nodes regulated by protein-protein interactions (PPIs). In particular, PPIs regulating the apoptotic response of a cell have 
been characterised, providing promising areas for drug discovery, for example, between members of the B-cell lymphoma 2 (Bcl-
2) family, the mouse double minute 2 (MDM2)-p53 interaction, and the interaction of second mitochondria-derived activator of 
caspases protein with X-linked inhibitor of apoptosis protein (Smac-XIAP). This chapter will describe each of these PPI targets 
and the discovery of small-molecule PPI inhibitor drugs that have entered clinical trials. 
PPI chemotherapy drugs 
Historically, extensive screening of natural products was used to identify compounds with cytotoxic activity for use in 
chemotherapy regimens. For a number of compounds investigated, the molecular mechanism of action was identified to be the 
disruption of a PPI (Table 1).  
The regulation of microtubule cycling by the polymerisation and depolymerisation of α,β-tubulin, is essential for the 
organisation of DNA during the M-phase of the cell cycle, and is targeted by a number of natural products from diverse sources. 
Isolated from plant sources, the vinca alkaloids e.g. vinblastine (1), and the taxoids e.g. taxol (2) were initially thought to share 
the same mechanism of action. However, detailed studies indicated that vinblastine (1) acts by binding into a hydrophobic 
groove at the interface of the α- and β-tubulin subunits at the ends of microtubules, and stabilises the microtubule at low 
concentrations, but induces depolymerisation at higher concentrations.2 In contrast, taxol (2) binds to the β-tubulin subunit 
close to the GTP-binding site.3–5 A conformational change is induced by drug binding that results in an unusually strong 
interaction between subunits and consequently microtubules grow in an uncontrolled manner. Isolated from marine sponges, 
the natural product Halichondrin B (3) and the simplified synthetic derivative Erubilin (4) also bind to microtubules close to the 
vinca binding site, and overlapping with the GTP-binding site, suppressing the growth of microtubules.6,7 Isolated from the 
myxobacteria Sorangium cellulosum, Epothilones e.g. 5 have a similar mechanism of action as the taxoids, and promote 
microtubule growth. 
The semi-synthetic derivative of rapamycin, temsirolimus (6) inhibits the kinase activity of the mammalian target of rapamycin 
protein (mTOR) by forming a protein-protein complex with the FK506 binding protein 12 (FKBP12).8 
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Druggability of PPIs 
Despite the serendipitous discovery of PPIs as cancer therapies, until recently the established view from medicinal chemists has 
been that PPI targets are significantly less ‘druggable’ than enzyme or receptor targets. The reasoning for this is based on the 
high surface area for PPI targets  (1500 – 4660 Å2) compared with other drug-protein interfaces (1200 - 2000 Å2), and their 
relatively high binding affinities (ΔG = -7.0 to -17.2 kcal/mol).9 Other analyses suggested that PPIs are more circular, flatter, less 
polar, and present fewer opportunities for H-bonding than enzyme or receptor drug targets.10 The negative outlook from these 
global analyses of PPIs, has been contradicted by detailed investigations of PPI binding sites, including alanine-scanning 
mutagenesis, that have revealed that many PPIs include small regions of high binding affinity called ‘hot-spots’ that can have 
attractive features for small molecule binding.11,12 Hot-spots may include the binding sites for large amino acid side chains on 
one protein that bind to small pockets on the partner protein, and may be circled by polar residues.13 ‘Hot segments’ are larger 
continuous epitopes that contribute the majority of the binding energy of a PPI.14 The most tractable of these for drug discovery 
are the interactions between a continuous peptide sequence of one peptide that interacts with a defined domain of the partner 
protein. The interfaces between protein and α-helical epitopes have demonstrated good tractability as drug targets, as 
exemplified by the development of Bcl-2 family and MDM2-p53 PPI inhibitors (vide infra). 
Targeting PPIs with small-molecules may have some advantages as they represent an under exploited class within the ‘druggable 
genome’ and may present opportunities to inhibit cellular pathways that would be difficult to approach though other target 
classes.15 PPIs may offer better opportunities for selectivity in comparison to competitive inhibition of enzymes at their 
substrate of co-factor binding sites due to the size and structural diversity of the interactions targeted. Unfortunately, the 
proposal that PPI inhibitors will offer a lower likelihood of developing resistance has not been borne out in clinical experience, 
especially in the case of MDM2-p53 inhibitors.16,17  
Bcl family inhibitors 
Biology 
The response of cells to a variety of signals resulting in programmed cell death or apoptosis is controlled by the PPIs of a family 
of proteins related to Bcl-2.18,19 Within the family, proteins can be grouped according to their role (Figure 1). The BH3-only 
proteins (e.g. Bcl-2-associated death promoter (Bad) and p53 upregulated modulator of apoptosis (PUMA)) act as initiators of 
apoptosis in response to cytokine deprivation, intracellular damage or oncogenic signalling, whereas truncated BH3 interacting-
domain death agonist (t-Bid) is activated by the death receptor and signalling via caspase 8. Activation of BH3 proteins induces 
the negative regulation of the pro-survival Bcl-2 proteins, and activation of the pro-apoptotic effector proteins, either Bcl-2-
associated protein (Bax) or Bcl-2-homologous antagonist killer (Bak), which disrupt the outer membrane of mitochondria and 
initiate the apoptotic cascade. 
Given the pivotal role of the Bcl-2 proteins in regulating cell death, it is not surprising that dysregulation of the pathway is 
strongly linked to the development of cancer. Overexpression of pro-survival proteins is linked to tumours, e.g. Bcl-2 
overexpression is found in 90% of follicular centre B cell lymphomas,20 and MCL-1 or BCL2L1 are amplified in a variety of 
tumours.21 Similarly, deletion or downregulation of BH3 initiator genes, BIM and PUMA has been observed in tumours.22–24 
Abnormalities in the Bcl-2 pathway are also associated with resistance to chemotherapy and radiotherapy.25  
The prospect of activating apoptosis in tumour cells where the Bcl-2 pathway is defective provides an attractive approach to 
new cancer therapies. Compounds have been sought that mimic the action of pro-apoptotic BH3 proteins by binding to Bcl-2 
family members to block their pro-survival action and so induce apoptosis directly. 
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Figure 1: Apoptotic signalling via the Bcl-family proteins. 
Structural biology and peptides 
NMR and X-ray studies with the B-cell lymphoma-extra large (Bcl-xL) protein provided a structural understanding of the domains 
involved in the anti- and pro-apoptotic activity of the protein.26 The tBH1, BH2 and BH3 domains of Bcl-xL form a hydrophobic 
cleft, which is the site for interactions with the pro-death proteins, Bax and Bak. The NMR solution structure of Bcl-xL bound to a 
Bak BH3 domain peptide shows the Bak peptide forms an amphipathic α-helix, which binds via the hydrophobic side chains of 
the Val74, Leu78, Ile81 and Ile85 residues into a hydrophobic groove on the surface of Bcl- xL (Figure 2).27 Investigations with 
mutant Bak peptides showed that the peptide binds as an amphipathic α-helix. Hydrophobic interactions between the side-
chains of Val574, Leu578, Ile581 and Ile585 of Bak and a hydrophobic groove formed by Tyr101, Leu108, Val126 and Phe146 on 
the surface of Bcl-xL contribute the majority of the interaction affinity.  In addition, Asp583 of the Bak peptide and Arg139 of  
Bcl-xL form an important electrostatic interaction. The identification of key interactions across a short peptide epitope 
encouraged the development of small molecule inhibitors of the interaction. 
A: B:  
Figure 2: NMR solution structure of Bcl-xL (green) bound to a peptide of residues 572-587 of Bak (red) (pdb 1BXL).27 A: ribbons; 
B: Bcl-xL surface (green) and Bak (red with grey surface) showing the key sidechain interactions. 
Small molecule Bcl family inhibitors 
α-Helix mimics based on a terephthalamide scaffold have been designed to mimic the side chain interactions of the Bak peptide 
as Bcl-xL inhibitors. Compound 7 inhibits the BH3 domain of Bak binding to Bcl-xL with a similar affinity to the peptide (Ki = 0.78 
μM)(Figure 3).28 Such compounds offer additional validation of the tractability of the Bcl-xL PPI as a target for small molecule 
inhibitors. However, the poor physicochemical properties of the compound (e.g. cLogP 7.4) prevent their optimisation as drugs. 
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Figure 3: Terephthalamide α-helix mimic (7). 
Screening of a library of natural products using NMR and fluorescence polarisation (FP) assays identified Gossypol (8) and 
Purpurogallin (9) as competitive inhibitors of the binding of a labelled BH3 peptide to Bcl-xL (Ki = 0.3 and 2.2 μM, 
respectively)(Figure 4). Binding to Bcl-xL BH3 binding pocket was confirmed by NMR. Gossypol induces induces multiple cellular 
effects, some of which can be attributed to it acting as a BH3 mimetic.29 Despite known liabilities of undesirable redox chemistry 
and protein reactivity for polyphenolic compounds,30 Gossypol and (R)-gossypol (AT-101) have been evaluated in clinical trials, 
but with limited efficacy observed in breast and prostate cancer.31–33 
A structure based approach was used to design a series of Bcl-2 inhibitors based on the docked structure of Gossypol (8) bound 
to Bcl-2.34 The most potent compound TW-37 (10) retains the extensive hydrogen-bonding of one triphenolic moeity combined 
with a larger hydrophobic group. The second half of 8 is replaced with a hydrophobic amide that allows more extensive contacts 
with the BH3 binding pocket resulting in improved potency. 10 inhibits Bcl-2, Bcl-xL, and induced myeloid leukemia cell 
differentiation protein (Mcl-1) interactions (Ki = 0.29, 1.1. and 0.26 μM, respectively) and induces apoptosis in the PC3 prostate 
cancer cell line (GI50 = 200 nM). 
 
Figure 4: Bcl-2 inhibitors Gossypol (8),Purpurogallin (9), and TW-37 (10). 
Fragment based screening offers an alternative to the optimisation of relatively high molecular weight hits from screening 
library compounds or natural products. Bcl-2 family inhibitors have been discovered and optimised using “SAR by NMR”. This is a 
two step method, in which the first step identifies low molecular weight fragments by observing chemical shift changes in the 
15N- or 1H-HSQC NMR spectrum of the protein on binding of the ligand. In the second step, additional fragments occupying 
different binding sites close to the first fragment hits are identified. NMR or X-ray crystallography are used to determine binding 
site and orientation of both fragments prior to the design of a suitable linking group. The linked fragments should result in a 
higher affinity ligand that accesses both binding sites.35 
Fragments binding to two subpockets of the BH3 interacting-domain death agonist (Bid) BH3 domain were identified in an NMR 
screen.36 The interaction sites of the fragments were mapped to specific amino acids on the Bid surface using additional NMR 
experiments and docking used to determine the likely binding modes. A small library of sulfonamides was prepared to evaluate 
linking of the fragments together, giving rise to sulfonamide 11 (Figure 5). Binding of 11 to the Bid BH3 domain was confirmed 
by NMR. Compound 11 was able to inhibit t-Bid induced Smac release in a mitochondrial assay and t-Bid induced apoptosis in 
transformed HeLa cells. Although further developments to this series have not been reported, this study confirmed the 
tractability of BH3 domains for NMR based fragment screening and the utility of the fragment linking approach. 
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Figure 5. Linking of Bid BH3 fragment hits. 
Another application of the SAR by NMR method gave rise to fragment hits for Bcl-xL that bound with millimolar potency. 
Modification of the fragment bound to Site 1 to an acylsulfonamide allowed linking to the second fragment site and maintained 
the acidic hydrogen (Figure 6). Parallel synthesis identified compound 12 (Ki = 36 nM), incorporating the 3-nitro-4-(2-
phenylthioethyl)amino phenol group that both acts as a linker and occupies the second fragment site. Structure-guided 
optimisation of 12 allowed the identification of modifications to reduce binding to human serum albumin (HSA) whilst 
maintaining affinity for Bcl-xL. The replacement of one phenyl ring with a piperazine ring reduced binding to HSA and allowed 
the introduction of a biphenyl group, as seen in compound 13, binding deep into a hydrophobic cleft on Bcl-xL that is not seen in 
the peptide bound structure. The addition of a basic group to the thioethylaminoethyl group further reduced HSA binding giving 
ABT-737 (13).37,38  
 
 
 
A: 
 
B:  C: D:  
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E:  
 
Figure 6: A: Linking of Bcl-xL bound fragments and optimisation by linking and structure-based design; B: solvent accessible 
surface of the NMR structure of Bcl-xL with 12 (green) bound (1YSI), overlayed with fragments (magenta) from 1YSG; C: solvent 
accessible surface of the NMR structure of Bcl-xL with 13 (green) bound (2O2N); D: solvent accessible surface of the X-ray 
structure of Bcl-xL with 14 (green) bound (4LVT); E: chemical structure of ABT-737 (10). 
 
ABT-737 (14) binds potently (Ki ≤ 1 nM) to Bcl-xL, Bcl-2, and Bcl-2-like protein 2 (Bcl-w) proteins, but less well to family members 
with lower homology, e.g. B-cell lymphoma/leukemia 11B protein (Bcl-B), Mcl-1 and Bcl-2-related protein A1 (Ki  = 460 nM and > 
1000 nM, respectively). In cells, 14 acts in a similar manner to an apoptosis sensitising Bad-BH3 peptide by binding to and 
inhibiting anti-apoptotic Bcl-2 proteins thus removing their protection from apoptosis. 14 does not directly cause cytochrome c 
release or directly activate the pro-apoptotic proteins Bak and Bax. 14 showed synergism in combination with 
chemotherapeutics (2-20 fold) and radiation (2-4 fold). 14 induced tumour regression in Bcl-2 overexpressing small cell lung 
cancer (SCLC) xenografts (100 mg/kg/day ip) and showed improved activity in combination with etoposide.39  
 
Promising results with ABT-737 prompted further rounds of structure-guided optimisation resulting in Navitoclax (ABT-263, 
15).40 In this case modifications were designed that did not disrupt the core binding motif and aimed to optimise aqueous 
solubility, cellular activity, and ultimately oral bioavailability. Modulation of the acidity of the sulfonamide group by variation of 
the 3-nitro group enhanced oral bioavailability, and switching the basic dimethylamino group to a morpholine reduced 
metabolism and improved oral exposure. A 3-trifluoromethylsulfone group proved to be the optimal replacement for the nitro 
group. Modifications to the 4-chlorobiphenyl moiety gave improved metabolic stability and cellular activity when the internal 
phenyl ring was replaced with a cyclohexenyl or gem-dimethylcyclohexenyl group. ABT-263 (15) has a high molecular weight 
(974 Da) and falls outside of other commonly used drug-like parameters, indicating the difficulty of addressing relatively long 
lipophilic binding sites. However, 15 shows cellular activity including mechanism-based cytotoxicity in Bcl-2 or Bcl-xL dependent 
models, and has acceptable oral bioavailability and PK properties.41 In vivo efficacy with complete regressions was observed in 
SCLC and acute lymphoblastic leukaemia (ALL) based xenografts (100 mg/kg qd p.o.). Reversible thrombocytopenia was noted as 
a mechanism related toxicity.  
 
A selective Bcl-2 inhibitor was designed with the aim of avoiding the thrombocytopenia observed with 15, attributed to the 
inhibition of Bcl-xL, and so improving the theraputic window.42 In order to separate Bcl-2 binding from Bcl-xL , a series of 
compounds was prepared starting from 15 with the removal or replacement of key binding moieties. Removal of the thiophenyl 
group of 15 (e.g. 16) allowed the key hydrophobic interaction to be achieved from a different vector with an azaindole group, 
and optimisation of the gem-dimethylcyclohexenyl group resulted in the discovery of venatoclax (ABT-191, 17)(Figure 7). 
Venatoclax (17) is a potent Bcl-2 inhibitor (Ki < 0.01 nM) with good selectivity over Bcl-xL and Bcl-w  (Ki = 48 and 245 nM, 
respectively). Selective cellular activity was seen for 17 in Bcl-2 dependent lines but not in Bcl-xL lines. In vivo antitumour activity 
was demonstrated for 17 in a selection of haematological tumour xenografts on a single oral dose. Ex vivo studies with human 
platelets showed that 17 was significantly less toxic than 15.  
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Figure 7: Design evolution of ABT-191 (17) from ABT-263 (15). 
 
Obatoclax (18) was identified in an FP assay measuring the displacement of a BH3 peptide from Bcl-2 family proteins as an 
inhibitor Bcl-2, Bcl-xL, Mcl-1, Bcl-w, A1, and Bcl-B (Ki ≈ 1-7 μM).43 Docking to the Bcl-2 NMR structure predicted that 18 binds to 
the BH3 binding groove in a hydrophobic pocket.  The hydrophobicity of 18 (cLogP > 4) was expected to favour membrane 
localisation, so studies with isolated mitochondria were used to demonstrate disruption of Mcl-1-Bak interactions. In whole 
cells, treatment with 18 initiates apoptosis, and is able to overcome Mcl-1 overexpression induced resistance to the Bcl-2 
inhibitor ABT-737 (14) and bortezomib. Single agent antitumour activity was demonstrated in SCID mice bearing human C33A 
cervical carcinoma tumors with IV dosing at 0.25 and 0.5 mg/kg. A Phase I dose finding study with obatoclax in various tumour 
types by IV infusion established the tolerability and pharmacokinetics of the drug with some indication of clinical activity.44  
 
        
 
Figure 8: Obatoclax (18) and bendamustine (19) 
 
Clinical development of Bcl-2 inhibitors 
Three Bcl-2 family inhibitors have progressed to clinical trials. Given the central role Bcl-2 family proteins play in the 
development of many lymphomas, this has been a key focus of clinical studies. A Phase I study with the pan Bcl-family inhibitor 
Navitoclax (15) in relapsed or refractory lymphoid malignancies established the optimum dosing regimen, pharmacokinetics, 
pharmacodynamics and tolerability of the drug and demonstrated some efficacy.45 Chronic lymphocytic leukemia (CLL) is 
characterised by over-expression of Bcl-2, and a Phase I study in CLL with 15 demonstrated substantial efficacy.46  In SCLC and 
other solid tumours, a Phase I clinical trial with 15, under intermittent or continuous oral dosing schedules, established a 
maximum tolerated dose and demonstrated the safety of the drug and antitumour activity was observed.47 A Phase IIa single-
agent trial of 15 in SCLC also demonstrated safety and biomarker modulation, however, efficacy was limited.48 Clinical studies 
with 15 in solid tumours are ongoing as a single agent and in combination with other therapies.  
Despite promising results with 15, the Bcl-xL induced thrombocytopenia observed was dose limiting and so attention switched 
to the Bcl-2 selective inhibitor venatoclax (17).49 A single agent Phase I study of 17 in CLL and small lymphocytic leukemia (SLL) 
showed an 84% response rate in CLL patients without significant reports of thrombocytopenia.50 A Phase II study of 17 in ALL 
demonstrated activity in this indication, particularly in patents with a poor prognosis.51 A combination of 17 with the anti-CD20 
antibody rituximab was evaluated to determine the maximum tolerated dose and safety profile, producing an overall response 
rate of 88% with good tolerability.52 A phase 1b combination study of 17 with bendamustine (19) in relapsed non-Hodgkin 
lymphoma established the safety of the combination, and showed good evidence of efficacy.53 A Phase 2 study of 17 in relapsed 
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or refractory CLL patients with a chromosome 17p deletion showed an 80% response rate, demonstrating the effectiveness 
single agent 17 in a patient group that responds poorly to immunotherapy.54 On the basis of these results venatoclax (17) 
received accelerated clinical approval in the US and Europe. 
In a phase I trial with obatoclax (18) in advanced CLL acceptable safety, and phamacodynamic responses (Bax and Bak elevation) 
were observed. Modest single agent activity was seen with 1/26 patients achieving a partial response.55 
 
MDM2-p53 
Biology 
The p53 tumour suppressor acts as a central node in the cellular response to stress and DNA-damage.56 Activation of p53 
produces an active tetramer that can transcribe around 150 genes, giving rise to a number of cellular effects including initiating 
apoptosis, cell-cycle arrest, DNA-repair, senescence or altered metabolism.57 MDM2, itself a product of p53 mediated 
transcription, acts as a negative repressor of p53 by binding to and occluding the p53 transactivation domain and by acting as an 
E3-ubiquitin ligase, targeting the complex for proteasomal degradation.58,59 The MDM2-p53 interaction forms an autoregulatory 
feedback loop, ensuring that cellular activation of p53 is transient.  
 Amplification of the MDM2 gene and overexpression of MDM2 protein occurs in around 10% of common cancers. The highest 
incidence is found in hepatocellular carcinoma (44%), lung (15%), sarcomas and osteosarcomas (28%), and Hodgkin disease 
(67%).60 MDM2 overexpression overrides p53 activation and inactivates its tumour suppressor function, thus rendering the cells 
effectively p53 null.  
Inhibitors of the MDM2-p53 PPI have been sought as they should act to reactivate p53-mediated cell death by removing MDM2 
mediated repression of transcription. Tumour selectivity is predicted to result from the removal of a MDM2 block on pre-
existing DNA-damage or oncogenic activation signals, thus allowing p53-mediated activation of apoptosis. 
Structural biology and peptides 
The NMR structure of MDM2 reveals that the protein adopts multiple conformations,61 with residues 16-24 of the N-terminal 
region forming a flexible lid that closes over the p53 binding site.62 p53 easily displaces the lid to form a more stable complex.63 
The X-ray structure of a p53 peptide and MDM2 interaction shows the surface MDM2 forms a hydrophobic cleft into which the 
p53 peptide binds as an amphipathic α-helix (Figure 5A).64 Epitope scanning determined that three p53 residues, Phe19, Trp23, 
and Leu26, form the principle interactions with MDM2, secured by two intermolecular hydrogen-bonds, between the backbone 
of Phe19 of p53 and the Gln72 side chain of MDM2, and between the p53 Trp23 indole NH and the backbone carbonyl of Leu54 
from MDM2 (Figure 9A). Potent inhibitors of the MDM2-p53 interaction were discovered from synthetic peptide libraries, 
including the AP peptide (IC50 = 5 nM) that incorporates 6-chlorotryptophan, and phosphonomethylphenylalanine residues.65  
The X-ray structure of the AP peptide bound to MDM2 (Figure 9B) shows the 6-chlorotryptophan group occupies additional 
space below the Trp23 site, and makes additional van der Waals contacts with Phe86 and Ile99 of MDM2. 
Hydrocarbon stapled α-helical peptides e.g. SAH-p53-8, Ac-QSQQTF*NLWRLL*QN-NH2 (* indicates the position of the 
hydrocarbon staple), have shown excellent potency as MDM2-p53 inhibitors.66,67 The X-ray crystal structure of SAH-p53-8 bound 
to MDM2  shows that the key binding residues Phe19, Trp23, and Leu26 form part of a short α-helix that binds to MDM2 (Figure 
9C).68 SAH-p53-8 induces p53 mediated cytotoxicity in MDM2 overexpressing cells. Similarly, the stapled peptide ATSP-7041, Ac-
LTP*EYWAQAba*SAA-NH2,  is a potent dual inhibitor of both MDM2-p53 (Ki = 0.9 nM) and MDMX-p53 (Ki = 6.8 nM), which has 
been optimised for solubility, and cellular potency.69 The X-ray structure of ATSP-7041 bound to MDMX shows that the 
hydrocarbon staple makes significant interactions with the protein and so contributes to binding affinity. ATSP-7041 showed 
activity in vivo in MDM2 and MDMX overexpressing human tumour xenografts. Other peptide derived MDM2-p53 inhibitors 
using alternative backbones have been invesigated with varying success  including reteroinverso D-peptides,70,71 β-peptides,72–74 
di-proline β-hairpins,75,76 and peptoids.77 
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A: B: C:  
Figure 9: X-ray structure of MDM2 (ribbon – green, surface – light green) bound to A) residues 15-29 of p53 showing the key 
hydrophobic sidechains (red) (pdb 1YCR), B) AP peptide (magenta)(pdb: 2GV2) C) SAH-p53-8 (purple)(pdb: 3V3B) 
Hit discovery and optimisation 
A variety of peptide mimetic approaches have been employed, using differing structures to array side chains in the appropriate 
orientation to recapitulate the peptide interaction with the MDM2 binding cleft (Figure 10).78  Terphenyls e.g. 20 demonstrated 
the validity of this approach.79  α-Helix mimics based on an oligoamide scaffold (21 and 22) were weak MDM2-p53 inhibitors.80,81 
The α-1,4 linked oligogalactose 23, bearing groups corresponding to the important p53 side chains from alternate C-6 and C-3 
hydroxyl groups, showed weak MDM3-p53 inhibitory activity.82 Although these approaches offer interesting insights into the 
binding requirements for MDM2, the compounds’ high molecular weights and poor drug-like properties prevent their 
development.  
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Figure 10: α-helix mimetic MDM2-p53 inhibitors 
The Nutlins are cis-imidazoline containing compounds, which were identified by HTS as inhibitors of MDM2-p53 with IC50 values 
in the 100-300 nM range (e.g. 24, IC50 = 90 nM).83 The series yielded the first reported X-ray and NMR structures of small 
molecules in complex with MDM2, showing that the heterocyclic scaffold arrays its substituents to mimic the side-chains of an 
α-helical peptide (Figure 11A, pdb 4J3E).84 Structure-guided optimisation enabled improvements to stability at the imidazoline 
heterocycle by the introduction of two cis-methyl groups and modification the metabolically labile 4-methoxy group to a tert-
butyl group. Additional potency and favourable PK properties were gained by the addition of a hydrophilic sulfone chain to the 
piperazine moiety, giving rise to the clinical candidate RG-7112 (25, IC50 = 18 nM). The X-ray co-crystal structure of MDM2 with 
25 (Figure 11B) shows it has a similar binding mode to Nutlin-3a, with the methylsulfone side chain extending into solvent.  
     
A:  B:  
Figure 11: X-ray structure of MDM2 (electrostatic surface) bound to A) Nutlin 3a 24 (green) (pdb 4J3E), B) RG7112 25 (pink)(pdb:  
4IPF) 
Modification of the Nutlin scaffold to a dihydroimidazothiazole resulted in the identification of a series of potent MDM2 
inhibitors, such as 26 (IC50 = 90 nM). Addition of the 6-methyl group is sufficient to stabilise the imidazoline ring to oxidation. 
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The bicyclic scaffold orientates the 3-isopropyl group into the MDM2 Phe19 pocket, and addition of an amide at the 4-position 
gave additional potency.85,86 The X-ray structure of 26 bound to MDM2 shows the imidazole ring and chlorophenyl groups 
occupying similar space to the Nutlin series (Figure 12A). The thiazole and isopropyl groups fill space occupied by the 
alkoxyphenyl group of 24, and the amide side-chain occupies a surface groove formed by the movement of a flexible loop. 
Interactions in the Trp23 binding pocket were optimised by the addition of a 3-fluoro-4-chlorophenyl group, and the amide 
moiety was elaboration with a 4,7-diazaspiro[2,5]octane group giving DS-5272 (27, IC50 = 24 nM, Figure 12B).87 DS-5272 showed 
good cellular activity, solubility, microsomal stability and acceptable in vivo PK properties. Anti-tumour efficacy was 
demonstrated in a MDM2-amplified mouse xenograft model (50 mg/kg/qdx4 p.o.). The authors suggest that DS-5272 is a 
possible candidate for clinical development, but the structure of the clinical candidate DS-3032b has not been disclosed. 
 A:  B:  
Figure 12: A) X-ray structure of MDM2 (electrostatic surface) bound to dihydroimidazothiazole 26 (green) (pdb 3VZV), B) Design 
evolution of DS-5272 (27) from 26.  
A series of spirooxindoles, e.g. 28 (Ki = 86 nM),  were identified initially by substructure searching for oxindole containing natural 
products designed to mimic the tryptophan of p53 (Figure 7).88 Structure-based elaboration of the amide group and addition of a 
5-fluoro group resulted in improved potency, e.g. 29 (IC50 = 28 nM).89,90 The X-ray co-crystal structure of 29 bound to MDM2 
shows the oxindole ring occupying the Trp pocket, with hydrogen bonds between the oxindole NH and the backbone carbonyl of 
Val54, and His96 NH and the amide side-chain carbonyl group, the 3-chloro-2-fluorophenyl group fills the Leu pocket, and the t-
butyl group is in the Phe pocket (Figure 8). The diol MI-147 (31, IC50 = 16 nM) showed cellular activation of p53 and in vivo 
activity in an MDM2 amplified tumour xenograft. Importantly, spirooxindoles e.g. 30 were found to epimerise under oxidative 
conditions to diastereomeric mixtures and the most stable diastereoisomer proved to have improved potency and in vivo 
activity.91,92 
SAR405838 (32, Ki = 0.88 nM) was selected from a series of amides as it showed improved chemical and metabolic stability, in 
addition to potent MDM2 binding affinity, selectivity, and growth inhibitory activity.93 Spiroxindole 32 induced complete tumour 
regression in SJSA-1 mouse xenografts with a single oral dose (100 mg/kg) and on repeat dosing. The in vivo efficacy of 32 was 
also demonstrated in a multiple tumour types without MDM2 amplification. Consequently, 32 was selected as a clinical 
candidate from the spirooxindole series.  
Further structure-guided optimisation of the spirooxindole series aimed to remove instability due to epimerisation.94 
Replacement of the 2’-neopentyl group of 32 with a cyclohexyl ring removed one chiral centre and maintained interactions in 
the Phe19 pocket of MDM2. Introduction of a carboxylic acid to the amide side-chain improved cell-free potency with the 
bicyclo[2.2.2]octane moiety as a phenyl ring replacement conferring improved PK characteristics. The alkylation of the 
pyrollidine nitrogen was necessary to improve the cellular PD response of the compound. The resulting compound APG115 (33) 
showed anti-tumour efficacy in a SJSA-1 mouse xenograft model (100 mg/kg/qd p.o.) and has entered phase I clinical trials. 
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Figure 13: Design evolution of SAR405838 (32) from 28. 
 
Figure 14: X-ray structure of MDM2 (electrostatic surface) bound to oxindole 29 (green) (pdb 3LBL). 
 
 
Figure 15: Design of APG115 (33) from 32. 
The spirocyclic amide scaffold of spirooxindole 32 was simplified to a cyanopyrrolidine core allowing a “cis” configuration of 
aromatic groups e.g. 34 (IC50 = 196 nM).95  The X-ray co-crystal structure of 34 bound to MDM2 shows the 4-chlorophenyl ring 
occupying the Trp pocket, with a hydrogen bond between His96 NH and the amide side-chain carbonyl group, the  
3-chlorophenyl group fills the Leu pocket, with the cyano group projecting into solvent and the t-butyl group occupies the Phe 
pocket (Figure 16). The addition of fluoro substituents to both aromatic rings was found to improve MDM2 inhibitory potency. 
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Optimisation of the PK profile was achieved at the amide side chain substituent, that was also found to modulate cellular 
potency. A 4-benzenecarboxylic group gave the desired properties, and SAR studies around the ring revealed that the ortho-
methoxy group, 35 (RG7388), had the ideal combination of MDM2 binding affinity, cellular potency and selectivity. RG7388 (35) 
gave complete tumour regression in vivo in an SJSA-1 xenograft model (25 mg/kg p.o.), and a favourable PK profile. RG7388 (35) 
was selected as the second generation MDM2-p53 clinical trial candidate owing to its improved potency, cellular selectivity and 
PK properties over RG7112 (25). 
A:  B:  
Figure 16: A) X-ray structure of MDM2 (electrostatic surface) bound to cyanopyrrole 34 (green) (pdb 4JRG); B) Design evolution 
of RG7388 (35) from 34. 
Substituted piperidines, e.g. 36 (IC50 = 600 nM), were identified as hits from a FP-based HTS (Figure 17A).96 Introduction of a 2-
methoxyethoxyphenyl substituent gave improved potency and the alkyl substituent on the piperidine ring was found to be 
essential to promote the optimum conformation of the ring e.g. 37 (IC50 = 40 nM).97,98 The MDM2 bound X-ray structure of 36 
identified the main interactions as the trifluoromethylpyridine occupying the Phe19 pocket, the trifluoromethylphenyl residue 
projecting into the Trp23 pocket and the Leu26 pocket filled by the alkoxyphenyl group (Figure 17B). Structure-guided 
optimisation resulted in 38 (Figure 17C).99 A combination of a 2-trifluoromethylthiophene replacement for the 
trifluoromethylphenyl residue and a butanoic acid substituent to the alkoxyphenyl group gave a 5-fold improvement in potency 
and cellular activity (38, IC50 = 7 nM). Compound 38 showed single agent activity in an A549 tumour xenograft at 200 mg/kg qd 
and in combination with taxoids.  
A: 
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B:  C:  
Figure 17: A: Design of piperidine 38; X-ray structures of MDM2 (electrostatic surface) bound to B: piperidine 37 (green) (pdb 
5HMK) C: piperidine 38 (green) (pdb 5HMH). 
A structure-based design approach identified the piperidone series of inhibitors (e.g. AM-8553, 39, IC50 = 1.1 nM).100 An X-ray 
structure of 39 bound to MDM2 showed that the (3R)-carboxyl group at C3 forms a key interaction with His96, the  
4-chlorophenyl group occupies the Typ pocket, the 3-chlorophenyl group fills the Leu pocket and the N-alkyl chain projects into 
the Phe pocket (Figure 18A). Modifications to the N-substituent aimed to optimise interactions with the ‘glycine shelf’ region, a 
hydrophobic region on the surface of MDM2 formed by Gly58 (Figure 18B).101,102 Sulfone 40 (AMG 232, IC50 = 0.6 nM) showed 
excellent cell-free potency and cell growth inhibitory activity. Complete tumour regression in SJSA-1 xenografts observed (60 
mg/kg/qd p.o.), and so AMG 232 was selected for clinical trials.103 Additional SAR studies around the carboxylic acid moiety 
resulted in compounds with equivalent potency.104,105 
A:  B:  
Figure 18: X-ray structure of MDM2 (electrostatic surface) bound to A: AM-8553 39 (green) (pdb 4ERF) B: Design of AMG232 40. 
Rational design based on the X-ray structure of the AP peptide bound to MDM2 (Figure 5B) gave rise to the ‘central valine’ 
concept, resulting in the identification of substituted imidazole (41, IC50 = 30 nM)(Figure 19).106 Structure-guided modifications 
to optimise potency and solubility gave rise to compound 42 (IC50 = 2 nM), however, the cellular activity in this series is poor 
compared with other series displaying similar MDM2-p53 potency.107 
     
Figure 19: substituted imidazole MDM2-p53 inhibitors (41 and 42) 
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Virtual screening identified dihydroisoquinolinone 43 as a hit MDM2-p53 inhibitor (IC50 = 540 nM)(Figure 20A).108 An X-ray 
structure of 44 bound to MDM2 showed an unexpected binding mode, significantly different to most MDM2 inhibitors, whereby 
the Leu26 sub-pocket is occupied by the C7 ethyl ether and not a substituted phenyl ring as seen in the majority of other 
inhibitor series (Figure 20B). X-ray structure guided optimisation gave rise to 45 (IC50 = 8 nM) with excellent cellular activity 
(Figure 20C). An X-ray structure of 45 showed that chlorophenyl group requires to be in the (S)-configuration at C1 and showed 
opportunities for optimisation around in the Phe pocket occupied by the 4-pyridinyl group (Figure 20C). Replacement of the 
pyridyl group with a trans-cyclohexyl amine gave NVP-CGM097 (46, IC50 = 1.7 nM) with good cellular and ADME properties.109 
The X-ray structure of 46 bound to MDM2 shows the Trp23 pocket is filled by the C1 4-chlorophenyl group, the Leu26 pocket 
filled by the C7 isopropyl ether, and the Phe19 sub-pocket is occupied and extended by movement of the protein to 
accommodate the large amine side-chain (Figure 20D). NVP-CGM097 showed good PK properties in a number of mammalian 
species and induced tumour regression in SJSA-1 xenografts (30 mg/kg/qd p.o.). NVP-CGM097 (46) has been selected for clinical 
trials.  
 
B:   C:   D:  
Figure 20: A: Design evolution of NVP-CGM097 (46); X-ray structure of MDM2 (electrostatic surface) bound to B: 
dihydroisoquinolinone 43 (green) (pdb 4ZYC); C: dihydroisoquinolinone 45 (green) (pdb 4ZYI); D: NVP-CGM097 (46) (green) (pdb 
4ZYF). 
In an alternative approach, based on hit compound 41 structural considerations gave rise to a new scaffold comprising a 
substituted delta-lactam fused to a five membered ring. Substructure searching identified lactam 47 as a novel hit with modest 
potency (IC50 = 1.5 μM)(Figure 21).110 Elaboration of hit 47 identified structural requirements for potency including, introduction 
of a 5-chloropyridin-2-one moiety to occuy the Leu23 pocket and stack efficiently with His96. The clinical trial candidate from 
this series HDM-201 (48) was reported recently as a potent inhibitor with favourable PK and PD profiles in animal studies.111  
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Figure 21: design of HDM-201 (48). 
Clinical development summary 
A number of MDM2-p53 inhibitors have entered clinical trials in solid and haematological malignancies (Table 2). A phase I 
clinical trial of of RG7112 25 in liposarcoma patients showed responses to therapy in 16 from 20 patients as partial response or 
stable disease.112 A poor PK profile was observed, PD markers for apoptosis and p53 activation showed a linear relationship with 
drug exposure and a food effect was noted.113 Some toxicity was observed including neutropenia and thrombocytopenia. A 
phase I trial of 25 in various leukemias showed activity in patients AML.114 The second generation inhibitor RG7388 (35) is under 
clinical investigation in a Phase III trial in AML.115,116 SAR405838 (32) was selected as the clinical candidate from the 
spirooxindole series and entered Phase I clinical trials as a single agent and in combination with the MEK1/2 inhibitor pimasertib. 
APG-115 (33) has entered Phase I clinical trials in advanced solid tumours and lymphomas as a single agent. 
A Phase I/II trial of AMG232 (40) is ongoing in metastatic melanoma, in combination with the MEK1/2 inhibitor trametinib and 
the B-Raf inhibitor dabrafinib. DS-3032b has been evaluated in a Phase I trial with some evidence of efficacy, and on target 
toxicity.117 Phase I trials of MK-8242 demonstrated some activity in liposarcoma and in AML.118,119 Results of trials of CGM097 
(46) and HDM201 (48) have not been reported to date. 
Overall, a number of agents have shown efficacy in both MDM2 amplified tumours e.g. liposarcomas and AML. Dose limiting p53 
mediated on target toxicity, including thrombocytopenia, has been reported. To date, no MDM2-p53 inhibitor has been 
approved, and the second generation inhibitor RG7388 has advanced the furthest. 
SMAC-XIAP 
Biology 
The inhibitor of apoptosis (IAP) family of proteins inhibit entry into apoptosis at the point of caspase activation.120 XIAP 
binds to the N-terminal amino acids of caspases 3,7, and 9 via its BIR domains and directly inhibits their activity. The activating 
Smac promotes apoptosis by binding to XIAP.121 The ML-IAP proteins bind to Smac, preventing its association with XIAP and so 
inhibiting apoptosis (Figure 22). The c-IAPs have a different mechanism, acting as negative regulators of the alternative NF-κB 
pathway by inhibiting NF-kappa-B-inducing kinase (NIK), and as activators of the classical NF-κB pathway by acting on Receptor-
interacting serine/threonine-protein kinase 1 (RIPK1). Amplification or overexpression of XIAP is has been observed in 
haematological and solid tumours, and is linked to poor prognosis and poor response to therapy. Similarly, amplification or 
overexpression of c-IAPs has been identified in a large variety of tumour types. The role of XIAP at the convergence of multiple 
apoptotic signaling pathways has made it an attractive target for therapeutic intervention. 
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Figure 22: The role of IAP proteins in caspase activation.  
Peptides and structural biology 
 The X-ray structure of Smac bound to XIAP shows the N-terminal four residues of Smac bound to a groove on the 
surface of XIAP (Figure 23A,B).122  Validation of targeting the Smac-IAP interaction as a therapeutic strategy was demonstrated 
using cell-penetrant synthetic peptides including seven N-terminal residues of Smac and a cell penetrating TAT domain were 
found to sensitise TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis and cytotoxic drug treatment in cells, but did 
not initiate apoptosis as single agents.123 N-Terminal Smac mimetic tetrapeptide libraries established the pharmacophore for the 
binding to BIR3 (Figure 23C).124 Modifications of the alanine residue at position 1 are limited to small L-amino acids, e.g. Abu, 
and retention of the NH is essential. Substitution at position 2 (Val) is tolerated, consistent with this residue projecting into 
solution, but D-amino acids are not tolerated. The proline ring at position 3 was required for activity, only the 4-membered 
azetidine substitution was tolerated.  Replacement of the isoleucine at position 4, with aromatic rings e.g. Phe or Nal, was 
favoured. Non-amino acid substituents at position 4 reduced the peptidic nature of the compounds and improved activity e.g. 
49 (KD = 12 nM). Substitution onto the proline ring added potency, e.g. 50 (KD = 5 nM). Structure based design of peptide 
inhibitors gave 51.125,126 
A:  B: C:  
D:    
Figure 23: X-ray structure of the BIR3 domain of XIAP complexed to Smac A: dimeric structure of XIAP (Blue) and Smac 
(Green); B: X-ray structure of the BIR3 domain of XIAP (electrostatic surface) complexed to Smac (green) (pdb 1G73); C: 
pharmacophore for tetrapeptide Smac-mimetic IAP inhibitors; D: structures of peptide IAP inhibitors 49-51.  
Hit discovery and optimisation 
Smac 
Active 
Caspase- 
3/7/9 
mitochondria 
ML-IAP XIAP 
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A number of structurally diverse of peptidomimetic scaffolds have been used to develop potent mono-valent Smac 
mimetics that show a range of selectivity between cIAP-1 and -2 and XIAP. Structure-based design of cIAP selective inhibitors 
revealed that variations at the P4 amino acid gave good selectivity, 2-pyrimidinyl compound (52) was a selective inhibitor of 
cIAP-1 and -2, but >2000-fold less potent vs XIAP.127 The selectivity was explained by modelling that showed an adverse lone-pair 
interaction in the P4 binding pocket between the pyrimidine nitrogens and the hydroxyl of Thr308 in XIAP, that is not seen for 
Arg313 in IAP-1. Structure-based design established the [7,5]-bicycle as a suitable dipeptide replacement for the second and 
third amino acid positions (Figure 24).128 Compound 53 showed potent inhibition of BIR3-IAP interactions and was cytotoxic as a 
single agent and in combination with doxorubicin. 
A:  B:    
Figure 24: A: X-ray structure of the BIR3 domain of XIAP complexed to 49 (green) (pdb 2I3I); B: XIAP inhibitors 52 and 53. 
Smac mimetic AT-406 (Figure 25, 54) incorporates a [5,8]-fused bicyclic replacement for residues 2 and 3 and is 
predicted to make additional hydrophobic contacts from the amide sidechain to Trp323 in the XIAP BIR3 domain.129  AT-406 (54) 
is a pan-selective IAP inhibitor (BIR3 Kd = 4.4, 0.7, 1.9 nM XIAP, cIAP1, cIAP2, respectively), and is cytotoxic in a number of cell 
lines. AT-406 (54) shows good oral PK in a number of mammalian species. 
   
Figure 25: XIAP inhibitor AT-406 (54). 
In order to rapidly determine the optimal substititions of tetrapeptide Smac mimetics, solid-phase peptide libraries 
were employed.130 A scan of the P1-P3 positions identifed MeAla, ChGly, and Pro, for each position respectively. Similarly, a 
systematic scan of the P4 position showed a diphenylethylamine moieity conferred potency. Additional SAR studies at the P4 
position were restricted to amines connected to an aromatic ring by one or two carbons. The thiadiazole compound GDC-0152 
(55) showed improved potency (BIR3 Ki = 28, 17, 43 nM XIAP, cIAP1, cIAP2, respectively). The X-ray structure of 55 bound to a 
chimeric BIR3 domains (Figure 26) shows the thiadiazole ring positions the phenyl residue into the P4 pocket. 55 showed efficacy 
in a MDA-MD-231 breast cancer xenograft, and a reasonable PK profile. On the basis of these results 55 was selected for clinical 
trials. GDC-0917 (56) is a second generation IAP inhibitor which is orally active and has improved PK.131 
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A:   B:   
Figure 26: A: X-ray structure of cIAP1/XIAP chimeric BIR3 domain with 51; B: GDC-0152 (55) and GDC-0917 (56). 
  NMR and X-ray based fragment screening with XIAP-BIR3 domain identified weakly binding fragment 57, which bound 
with the piperazine ring in the P1 pocket (Figure 27A) and the piperidine ring in the P3 pocket.132 Elaboration of the fragment by 
the addition of a methyl group to access the alanine pocket and switching to a pyrrolidine amide gave 58 (XIAP-BIR3 IC50 = 52% 
at 1mM) (Figure 27B). Amide 55 (XIAP-BIR3 IC50 = 5.5 μM) was identified from a virtual screening library of amides and the gem-
dimethyl group added to improve potency and the metabolic stability of the azaindoline. Introduction of a methoxymethyl 
group on the piperazine ring improved potency (60), and the addition of a 6-benzyl group improved interactions with the P4 
pocket (61, XIAP-BIR3 IC50 = 0.16 μM). Elaboration of the piperazine substituent to an iso-indolinone resulted in ASTX660 (62) a 
potent inhibitor of XIAP and c-IAP1 that was selected for clinical trials.   
A:  B:  C:  D:   
E:  
Figure 27: Evolution of ASTX-660 (58). X-ray structure of XIAP-BIR3 (electrostatic surface, ligand green) with A: 57 (pdb 5C3H); B: 
58 (pdb 5C7B); C: 60 (pdb 5C84); D: 61 (pdb 5C83); E: Evolution of ASTX660 (62) from 57. 
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Birinapant (Figure 28, TL32711, 63) is a bivalent Smac-mimetic that shows potent XIAP and cIAP antagonism, and 
induces the downregulation of specific pools of cIAPs in cells.133,134 63 induced apoptosis in cell lines either as a single agent by 
inducing the formation of a RIPK1-caspase 8 protein complex. 63 has been shown to potentiate some chemotherapy drugs in a 
p53-independent manner. Single-agent anti-tumour activity was demonstrated in patient derived xenograft models of ovarian 
cancer, colorectal cancer, and melanoma. Birinapant 63 is currently undergoing clinical trials in solid and haemaotological 
malignancies.  
Clinical development summary 
A number of XIAP and c-IAP inhibitors are in clinical trials currently in solid and haematological malignancies, as single 
agents and in combination with chemotherapy or anti-PD1 antibody therapies (Table 3).135 In phase I trial GDC-0917 (52) was 
well tolerated and showed good PK and PD properties, 2/42 patients showed a complete response (one ovarian cancer and one 
MALT lymphoma), 4 patients had stable disease.131,136 A phase I trial of LCL161 (Figure 28, 64) showed the the drug was well 
tolerated and significant degradation of cIAP1 indicated a PD effect.137 Although clinical evaluation of IAP inhibitors is in the 
early stages, initial results are encouraging. 
 
Figure 28: clinical trial candidates Birinipant (63) and LCL161 (64). 
<Table 3> 
Outlook and Conclusions 
PPIs are a challenging class of molecular targets to address with small-molecule inhibitors. The importance of PPIs in the biology 
of cancer, and particularly the regulation of apoptosis, has stimulated considerable drug discovery effort. The application of 
modern technologies such as screening of virtual, fragment, and lead-like libraries, coupled with structure-based design has 
enabled the discovery of potent and selective PPI inhibitors. The inhibitors profiled in some cases stray outside the confines of 
the ‘rule-of-five’ emphasising the challenge of targeting large, lipophilic sites.138  
The first PPI inhibitor has been licenced for clinical use in CLL, demonstrating the efficacy of selective Bcl-2 inhibition. Clinical 
trials of MDM2-p53 and IAP inhibitors are at an earlier stage. Preliminary results with MDM2-p53 inhibitors show promise, but 
with the limitations of on-target toxicity. The IAP inhibitors show less toxicity and some efficacy.  
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 Tables 
Table 1: Natural product derived PPI drugs. 
Name Compound Structure 
Vinblastine 1 
 
Taxol 2 
 
Halichondrin 
B 
3 
 
Eribulin 4 
 
Epothilone B  
 
5  
 
 
23 
 
Temsirolimus 6 
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Table 2: MDM2 inhibitors in clinical trials. 
Compound Structure Company  Clinical trial Indications ID Reference 
RG7112 25 Roche Phase I Liposarcoma NCT00623870 112–114 
Idasanutlin 
RG7388 
35 Roche Phase III 
Acute myeloid 
leukemia 
NCT02545283 115,116 
SAR405838 32 Sanofi Phase I Liposarcoma NCT01636479  
APG-115 33 Ascentage Phase I 
solid tumors, 
lymphomas 
NCT02935907  
AMG232 40  Amgen Phase I/II 
Metastatic 
melanoma 
NCT02110355  
DS-3032b nd Daiich-Sankyo Phase 1 (x3) 
Solid tumours, 
Lymphomas, 
Haematological, 
Refactory Multiple 
Myeloma 
NCT01877382 117 
MK-8242 nd 
Merck Sharp & 
Dohme 
Phase I 
Solid tumours, 
AML 
NCT01463696 118,119 
CGM097 46 Novartis Phase I Solid tumours NCT01760525  
HDM201 48 Novartis 
Phase I/II 
combination 
with LEE011 
Liposarcoma NCT02343172  
 
Table 3: IAP inhibitors in clinical trials. 
Compound Structure Company  Clinical trial Indications ID Reference 
AT-406 54 Ascenta/Debiopharm Phase I/II 
Head and neck 
squamous cell 
carcinoma – 
combination with 
chemo-radiation 
NCT02022098 129 
GDC-0152  
(RG-7419) 
55 Roche (Genentech) Phase I Solid cancers NCT00977067 130 
GDC-0917 
(CUDC-427) 
56 Curis (Genentech) Phase I 
Lymphoma and 
solid tumours 
NCT01908413 131,136 
ASTX660 62 Astex Therapeutics Phase I/II 
Lymphoma and 
solid tumours 
NCT02503423 132 
Birinapant 
(TL32711) 
63 Tetralogic Pharma Phase I/II 
Soild tumours – 
combination with 
pembrolizumab 
NCT02587962 133,134 
AEG40826 
(HGS1029) 
nd 
Aegera and Human 
Genome Sciences 
Phase I Solid tumours NCT00708006 139 
LCL161 64 Novartis Phase II 
Multiple myeloma 
– combination 
with 
cyclophosphamide 
NCT01955434 137 
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